An interview with Killian O’Driscoll, NIBRT

What do you see as the next generation of changes in the industry?

There’s diversity in the product pipeline, the portfolio difference and different types of therapies being developed, from biosimilars to antibody drug conjugates, gene and cell therapies, and how the manufacturers will respond to them is a key challenge.

So some of the themes we’re hearing about are single use technologies, process integration, and then evolving into continuous manufacturing. There are also regulatory, manufacturing and scientific challenges in this area that need to be addressed.

What challenges are you seeing with companies who work with you?

There’s a broad range of challenges, people want to stay current with the latest technologies, and being compliant with the regulatory requirements. There’s also the challenge of manufacturing complex therapies. So it’s quite a dynamic environment, and there is further challenges in keeping staff current and up to date with the latest scientific developments is always a challenge and an opportunity

How can NIBRT address these requirements?

NIBRT’s role is to help the growth and development of the biotech sector in Ireland and internationally. We do that in two ways, by conducting training programmes and also by conducting applied research programmes to help both the manufacturers, academic communities and vendor communities. This way, we aim to make biopharmaceutical manufacturing as efficient and as effective as possible.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s